The Centers for Medicare & Medicaid Services (CMS) will seek advice from a panel of outside experts concerning drugs used by patients with chronic kidney disease, given concerns over possible heart dangers.
The drugs, known as erythropoiesis-stimulating agents (ESAs), have already weathered recent warnings and restrictions over their use in cancer patients that have caused doctors to lower doses.
More here.
